Trombolisis intravenosa con rtPA en el Stroke Isquémico Agudo. Eficacia y seguridad del programa instalado en el Hospital Universitario de la Fundación Favaloro / Intravenous thrombolysis with recombinant tissue plasminogen activator in the acute ischemic stroke

The study of the National Institute of Neurological Disorders and Stroke (NINDS) proved that the use of the recombinant tissue plasminogen activator (rtPA) within the first 3 hours since the beginning of the symptomatology of the acute ischemis stroke (AIS) is as well safe as effective...These preliminary data reported in our study show that a strict protocol of thrombolysis IV with rtPA in AIS is feasible to be carried on with good results in a high complexity Center.

Trasplante pulmonar en la enfermedad respiratoria avanzada. Características poblacionales y evolución de los pacientes en evaluación y espera pre-trasplante / Lung transplantation for end-staged lung disease. Population characteristics and evolution of patients for evaluation and in transplant waiting list

El número de pacientes que se incluyen en programas de transplante pulmonar es creciente y su sobrevida en lista de espera depende de la posibilidad de acceder a un TxP así como de la progresión de la enfermedad de base. El objetivo de este trabajo es analizar la evolución y sobrevida de los pacientes con enfermedad respiratoria avanzada (ERA) evaluados para trasplante uni y bipulmonar

Trasplante pulmonar en la enfermedad respiratoria avanzada. Características poblacionales y evolución de los pacientes en evaluación y espera pre-trasplante / Lung transplantation for end-staged lung disease. Population characteristics and evolution of patients for evaluation and in transplant waiting list

El número de pacientes que se incluyen en programas de transplante pulmonar es creciente y su sobrevida en lista de espera depende de la posibilidad de acceder a un TxP así como de la progresión de la enfermedad de base. El objetivo de este trabajo es analizar la evolución y sobrevida de los pacientes con enfermedad respiratoria avanzada (ERA) evaluados para trasplante uni y bipulmonar

Early occlusion of coronary by-pass associated with the presence of factor V Leiden and the prothrombin 20210A allele: case report.

The presence of factor V Leiden mutation and the variation of the prothrombin gene 20210GA have been described as additional risk factors for arterial thrombosis when other acquired or metabolic risk factors are present. We report here a 56-year-old man who developed coronary artery disease since 1980 without any known risk factor and underwent a cardiopulmonary by-pass in 1997. In the first month after surgery, he became symptomatic, and an angiography showed complete occlusion of the grafts and some native coronary arteries. Three months after the second cardiopulmonary by-pass, a thrombophilic state was searched, and plasma levels of lipoprotein (a) (LPa) were measured. The patient is heterozygous for factor V Leiden mutation and has the variation 20210GA of the prothrombin gene and high levels of LPa. These findings induced us to add oral anticoagulation to the aspirin treatment, and the patient is in a good condition 11 months later.